Nội dung được dịch bởi AI, chỉ mang tính chất tham khảo
Tác động lâu dài của các loại chất ức chế 3-hydroxy-3-methylglutaryl coenzyme A reductase đối với sự thay đổi tốc độ lọc cầu thận tại Hàn Quốc
Tóm tắt
Chỉ có một số ít các nghiên cứu theo dõi lâu dài đã so sánh sự thay đổi chức năng thận theo loại statin được sử dụng ở Hàn Quốc. Nghiên cứu này so sánh tác động lâu dài của cường độ và loại statin lên sự thay đổi của tốc độ lọc cầu thận (GFR). Chúng tôi đã thu thập dữ liệu của những bệnh nhân lần đầu tiên sử dụng statin. Chúng tôi phân tích liệu các loại statin khác nhau có ảnh hưởng đến sự thay đổi GFR ở thời điểm 3 tháng sau khi bắt đầu và 4 năm sau đó hay không. Chúng tôi đã bao gồm 3678 bệnh nhân và phân tích sự thay đổi GFR. GFR giảm trung bình 3.2% ± 0.4% sau 4 năm kể từ lần kê đơn statin đầu tiên, cho thấy sự suy giảm đáng kể về mặt thống kê (từ 83.5 ± 0.4 mL/phút/1.73 m2 xuống 79.9 ± 0.4 mL/phút/1.73 m2, P < 0.001). Khi so sánh GFR giữa các loại statin khác nhau, có sự khác biệt đáng kể giữa atorvastatin và fluvastatin (–5.3% ± 0.7% so với 1.2% ± 2.2%, P < 0.05) và giữa atorvastatin và simvastatin (–5.3% ± 0.7% so với –0.7% ± 0.8%, P < 0.05). Đối với pitavastatin (tỷ lệ odds [OR]= 0.64, khoảng tin cậy [CI]= 0.46–0.87, P < 0.005) và simvastatin (OR = 0.69, CI = 0.53–0.91, P < 0.008), tỷ lệ GFR giảm dưới 60 mL/phút/1.73 m2 thấp hơn đáng kể so với atorvastatin. Liên quan đến việc sử dụng statin lâu dài, GFR thay đổi theo loại statin. Công trình này là nghiên cứu đầu tiên tại Hàn Quốc so sánh từng loại statin theo sự thay đổi của GFR sau khi kê đơn statin.
Từ khóa
#statin #tốc độ lọc cầu thận #atorvastatin #fluvastatin #simvastatin #pitavastatin #Hàn Quốc #nghiên cứu theo dõi lâu dàiTài liệu tham khảo
Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319(1): 24–33
Lee MH, Kim HC, Ahn SV, Hur NW, Choi DP, Park CG, Suh I. Prevalence of dyslipidemia among Korean adults: Korea national health and nutrition survey 1998–2005. Diabetes Metab J 2012; 36(1): 43–55
European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines(CPG) 2008–2010 and 2010–2012 Committees. EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology(ESC) and the European Atherosclerosis Society(EAS). Eur Heart J 2011; 32(14): 1769–1818
Ahn JH, Yu JH, Ko SH, Kwon HS, Kim DJ, Kim JH, Kim CS, Song KH, Won JC, Lim S, Choi SH, Han K, Cha BY, Kim NH; Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Prevalence and determinants of diabetic nephropathy in Korea: Korea national health and nutrition examination survey. Diabetes Metab J 2014; 38(2): 109–119
Kang YH, Jeong DW, Son SM. Prevalence of reduced kidney function by estimated glomerular filtration rate using an equation based on creatinine and cystatin C in metabolic syndrome and its components in Korean adults. Endocrinol Metab(Seoul) 2016; 31(3): 446–453
Kidney Disease Outcomes Quality Initiative(K/DOQI) Group. K/ DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41: I–IV, S1–91
Agarwal R. Effects of statins on renal function. Am J Cardiol 2006; 97(5): 748–755
Moon BS, Kim J, Kim JH, Hyun YY, Park SE, Oh HG, Park CY, Lee WY, Oh KW, Lee KB, Kim H, Park SW, Rhee EJ. Eligibility for statin treatment in Korean subjects with reduced renal function: an observational study. Endocrinol Metab(Seoul) 2016; 31(3): 402–409
Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation(GREACE) study. J Clin Pathol 2004; 57(7): 728–734
Fried LF, Forrest KY, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications 2001; 15(3): 113–119
Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005; 112(2): 171–178
Lee TM, Lin MS, Tsai CH, Chang NC. Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney Int 2005; 68(2): 779–787
Su X, Zhang L, Lv J, Wang J, Hou W, Xie X, Zhang H. Effect of statins on kidney disease outcomes: a systematic review and metaanalysis. Am J Kidney Dis 2016; 67(6): 881–892
Kendrick J, Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis 2010; 55(1): 42–49
Acharya T, Huang J, Tringali S, Frei CR, Mortensen EM, Mansi IA. Statin use and the risk of kidney disease with long-term follow-up(8.4-year study). Am J Cardiol 2016; 117(4): 647–655
Garcia MM, Varela CG, Silva PF, Lima PR, Góes PM, Rodrigues MG, Silva MdeL, Ladeia AM, Guimarães AC, Correia LC. Endothelial effect of statin therapy at a high dose versus low dose associated with ezetimibe. Arq Bras Cardiol 2016; 106(4): 279–288
Clarke AT, Johnson PC, Hall GC, Ford I, Mills PR. High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort. PLoS One 2016; 11(3): e0151587
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889–2934
Kim HS, Lee H, Park B, Park S, Kim H, Lee SH, Cho JH, Yoon KH, Cha BY, Kim JH, Choi IY. Comparative analysis of the efficacy of low-and moderate-intensity statins in Korea. Int J Clin Pharmacol Ther 2016; 54(11): 864–871
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130(6): 461–470
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1–S266
Centers for Disease Control and Prevention. Public health and aging: trends in aging—United States and worldwide. JAMA 2003; 289(11): 1371–1373
Chae HB, Lee SY, Kim NH, Han KJ, Lee TH, Jang CM, Yoo KM, Park HJ, Lee MK, Jeon WS, Park SE, Moon HS, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. Age is the strongest effector for the relationship between estimated glomerular filtration rate and coronary artery calcification in apparently healthy Korean adults. Endocrinol Metab(Seoul) 2014; 29(3): 312–319
Fang Q, Zou C, Zhong P, Lin F, Li W, Wang L, Zhang Y, Zheng C, Wang Y, Li X, Liang G. EGFR mediates hyperlipidemia-induced renal injury via regulating inflammation and oxidative stress: the detrimental role and mechanism of EGFR activation. Oncotarget 2016; 7(17): 24361–24373
Campese VM, Nadim MK, Epstein M. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol 2005; 16(Suppl 1): S11–S17
Verma A, Ranganna KM, Reddy RS, Verma M, Gordon NF. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol 2005; 96(9): 1290–1292
Yasuda G, Kuji T, Hasegawa K, Ogawa N, Shimura G, Ando D, Umemura S. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. Ren Fail 2004; 26(4): 411–418
Gueler F, Rong S, Park JK, Fiebeler A, Menne J, Elger M, Mueller DN, Hampich F, Dechend R, Kunter U, Luft FC, Haller H. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol 2002; 13(9): 2288–2298
Sharyo S, Yokota-Ikeda N, Mori M, Kumagai K, Uchida K, Ito K, Burne-Taney MJ, Rabb H, Ikeda M. Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway. Kidney Int 2008; 74(5): 577–584
Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, Ricciardelli B, Donnarumma E, Bianco A, Zabatta MA, Troncone G, Colombo A, Briguori C, Condorelli G. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012; 126(25): 3008–3016
Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets(TNT) study. Clin J Am Soc Nephrol 2007; 2(6): 1131–1139
Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y; MEGA Study Group. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis 2009; 206(2): 512–517
Kaneko H, Yajima J, Oikawa Y, Tanaka S, Fukamachi D, Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Kano H, Uejima T, Koike A, Nagashima K, Kirigaya H, Sawada H, Aizawa T, Yamashita T. Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. Heart Vessels 2014; 29(1): 21–28
Shah S, Paparello J, Danesh FR. Effects of statin therapy on the progression of chronic kidney disease. Adv Chronic Kidney Dis 2005; 12(2): 187–195
Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61(1): 297–304
Sakaeda T, Kadoyama K, Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS One 2011; 6(12): e28124
de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, Monyak JT, Parving HH, Remuzzi G, Sowers JR, Vidt DG. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease(PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol 2015; 3(3): 181–190
Albert MA, Glynn RJ, Fonseca FA, Lorenzatti AJ, Ferdinand KC, MacFadyen JG, Ridker PM. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin(JUPITER) trial. Am Heart J 2011; 162(1): 106–14.e2
Kwon JE, Kim Y, Hyun S,Won H, Shin SY, Lee KJ, Kim SW, Kim TH, Kim CJ. Cholesterol lowering effects of low-dose statins in Korean patients. J Lipid Atheroscler 2014; 3(1): 21–28(in Korean)
Kim M, Kim HK, Ahn Y, Park H, Jeong MH, Cho JG, Park JC, Kim YJ, Cho MC, Kim CJ. Comparing high-intensity versus low-to moderate-intensity statin therapy in Korean patients with acute myocardial infarction. J Lipid Atheroscler 2014; 3(2): 97–104(in Korean)
Kim HS, Kim H, Jeong YJ, Kim TM, Yang SJ, Baik SJ, Lee SH, Cho JH, Choi IY, Yoon KH. Development of clinical data mart of HMG-CoA r(HMG-CoA) Reductase inhibitor for varied clinical research. Endocrinol Metab(Seoul) 2017; 32(1): 90–98
Cho KW, Kim SM, An CH, Chae YM. Diffusion of electronic medical record based public hospital information systems. Healthc Inform Res 2015; 21(3): 175–183